Navigation Links
AIT Laboratories Launches New Tools for Prescription Compliance Monitoring
Date:10/10/2011

INDIANAPOLIS, Oct. 10, 2011 /PRNewswire/ -- Chronic pain affects an estimated 116 million adults in the U.S.—more than the number affected by heart disease, diabetes, and cancer combined, according to a recent report by the Institute of Medicine.  At the same time, prescriptions for opioids have increased over the last ten years by 48%, contributing to the nation's growing battle with prescription drug abuse, according to a report by the U.S. Food and Drug Administration.

As a result, healthcare practitioners treating patients with chronic pain are in need of services to help manage the care of their patients while making sure that patients are compliant with their prescribed medications.

AIT Laboratories is launching AIT Pathways, a new suite of services for prescription compliance monitoring that provides data and information to healthcare practitioners who are trying to find a balance between safety, efficacy, and risk in order to meet their patients' needs.

"It isn't enough anymore to just do a urine or a blood test on a patient being prescribed opioids for the management of chronic pain. It is increasingly important to assist the healthcare practitioner in understanding his/her entire patient population and how to better manage the compliance of their patients while they continue to treat patients with legitimate chronic pain," said AIT Manager of Scientific Education Josh Gunn, Ph.D.

AIT is now offering healthcare practitioners the following:

Urine Baselines:

  • A urine baseline study offers a comprehensive look at a healthcare practitioner's practice with the ability to benchmark the office's compliance on a state and national level. Based on nearly 200,000 urine samples tested by AIT in 2010, the company is able to show a state-by-state comparison of non-compliance. To view the percentages of non-compliance by state, visit

SOURCE AIT Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
6. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
7. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... 1, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... corporate presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief ... a business and financial update on Wednesday, July 8, 2015 ... A live audio webcast of the presentation may be ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – today announced that they will welcome four new members to their industry ...
(Date:7/1/2015)... ... 2015 , ... Ormco Corporation, a leading manufacturer and provider ... for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual Damon ... in its mission to provide free quality orthodontic care to individuals with financial ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of the ... DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, commercial ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Collaborative ... the New York Community Trust. The grant will allow CCF to improve quality of ... practices. , CCF was formed to respond to many changes in New York’s Medicaid ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... (Nov. 20, 2010) Columbia University Medical Center will ... researcher who has made important advances in understanding the ... disease. A promising young investigator at Columbia will also ... for disordered lipid metabolism in diabetes. ...
... By Madonna Behen HealthDay Reporter , FRIDAY, ... rising on U.S. college campuses, college officials are trying various ... that targeted off-campus boozing shows some promise, researchers say. ... California cut the level of heavy drinking at private parties ...
... Houston (UH) physicists are using complex computer simulations to ... malfunctioning, may cause Alzheimer,s and cancer. Margaret ... Samiotakis, a physics Ph.D. student, described their findings in ... kinase (PGK) are strongly perturbed by macromolecular crowding," published ...
... construct an online interactive world map which gives stark facts ... and following the birth of their child. Social scientists ... collaboration with the White Ribbon Alliance for Safe Motherhood and ... excess of 160,000 called ,The Atlas of Birth, which also ...
... News) -- People who develop gastroenteritis from E. coli-contaminated ... pressure, kidney problems and heart disease later in life, ... the Walkerton Health Study, which evaluated the long-term health ... (commonly known as stomach flu) in May 2000 after ...
... (HealthDay News) -- Among patients with kidney disease in ... some Hispanics, get sicker faster than whites do, researchers ... chronic kidney disease has been established," study co-author Dr. ... Francisco, said in a news release from the American ...
Cached Medicine News:Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 3Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 4Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 2Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 3Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 2Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 3Health News:Online map of maternal health to inform world leaders 2Health News:E. Coli Could Have Long Term Effect on Heart 2Health News:Race Seems to Impact Rate of Kidney Function Decline 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: